Oncobax® AM
Immunotherapy-resistant Non-Small Cell Lung Cancer (NSCLC)
Phase 2Active
Key Facts
Indication
Immunotherapy-resistant Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 2
Status
Active
Company
About EverImmune
EverImmune is a clinical-stage biotech developing a novel class of cancer treatments based on the gut microbiome. The company's core technology involves identifying and formulating specific bacterial strains or consortia, branded as Oncobax®, which are designed to convert 'cold' tumors responsive to immunotherapy into 'hot' ones. Its lead candidate, Oncobax® AM, is a specific strain of Akkermansia muciniphila being prepared for a Phase 2 trial in non-small cell lung cancer (NSCLC) patients resistant to immunotherapy. EverImmune operates as a private, pre-revenue company advancing a pipeline of live biotherapeutic products through strategic research and planned clinical trials.
View full company profile